| Recruiting | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV N Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | 2024-01-11 |
| Recruiting | A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia Cachexia | Phase 1 | 2023-06-13 |
| Active Not Recruiting | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Renal Cell Carcinoma | Phase 3 | 2021-09-09 |
| Completed | A Phase 1 Study of AV-380 in Healthy Subjects Cachexia | Phase 1 | 2021-02-22 |
| Withdrawn | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemi Acute Myeloid Leukemia | Phase 2 | 2020-01-31 |
| Terminated | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 1 / Phase 2 | 2019-09-30 |
| Completed | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC Carcinoma, Renal Cell | Phase 1 / Phase 2 | 2017-03-22 |
| Completed | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Ca Carcinoma, Renal Cell | Phase 3 | 2016-05-24 |
| Terminated | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreat Non-small Cell Lung Cancer | Phase 2 | 2014-11-01 |
| Terminated | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Brea Triple Negative Breast Cancer | Phase 2 | 2012-11-01 |
| Terminated | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC Metastatic Renal Cell Carcinoma | Phase 2 | 2012-07-01 |
| Completed | A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function Hepatic Impairment | Phase 1 | 2012-05-01 |
| Completed | A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumor Solid Tumors | Phase 1 | 2012-05-01 |
| Completed | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as Firs Colorectal Cancer | Phase 2 | 2011-12-01 |
| Completed | A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subject Healthy | Phase 1 | 2011-05-01 |
| Completed | A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects Healthy | Phase 1 | 2011-05-01 |
| Completed | A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib ( Food Effect of Tivozanib in Health Subjects | Phase 1 | 2011-02-01 |
| Completed | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma Renal Cell Carcinoma | Phase 2 | 2011-01-01 |
| Completed | A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumor Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer | Phase 1 | 2010-11-01 |
| Completed | A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dy Advanced Solid Tumors | Phase 1 | 2010-10-01 |
| Terminated | A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib P Solid Tumors | N/A | 2010-06-01 |
| Completed | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Advanced Renal Cell Carcinoma | Phase 3 | 2010-03-01 |
| Completed | A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer Carcinoma, Non-Small Cell-Lung, Lung Neoplasms, Lung Cancer | Phase 1 / Phase 2 | 2009-12-01 |
| Completed | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Advanced Renal Cell Carcinoma | Phase 3 | 2009-12-01 |
| Completed | A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Malignant Solid Tumour, Liver Metastases | Phase 1 | 2009-08-01 |
| Completed | A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects Metastatic Breast Cancer | Phase 1 | 2009-02-01 |
| Completed | An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cance Carcinoma, Non-Small-Cell Lung | Phase 1 | 2009-01-01 |
| Completed | A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Malignant Solid Tumor, Lymphomas, Multiple Myeloma | Phase 1 | 2008-09-01 |
| Completed | Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestina Colorectal Cancer, Gastrointestinal Cancer | Phase 1 | 2008-06-01 |
| Completed | A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Te Renal Cell Carcinoma | Phase 1 | 2007-11-01 |
| Completed | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma, Renal Cell | Phase 2 | 2007-10-01 |
| Completed | A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Pati Advanced Cancer, Refractory Cancer | Phase 1 | 2007-10-01 |
| Terminated | Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies Tumor | Phase 1 | 2006-10-01 |
| No Longer Available | Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient Mullerian Mixed Tumor of Ovary | — | — |